DelveInsight’s Chemotherapy Induced Neutropenia Market report offers comprehensive coverage of the current treatment practices, pipeline drugs, Chemotherapy Induced Neutropenia market share of the individual therapies, current and forecasted CIN market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

 

Some of the key takeaways from the Chemotherapy Induced Neutropenia Market report: 

• The Chemotherapy Induced Neutropenia market size of Neupogen and Neulasta was USD 216 million and USD 2,450 million in 2020 in the 7MM.
• The total estimated number of cancer patients on chemotherapy was 1,790,618 in 2020 in the 7MM. 
• The Chemotherapy Induced Neutropenia epidemiological analysis for the US demonstrated Breast cancer accounting for the maximum number of Chemotherapy Induced Neutropenia prevalence out of various forms of cancers such as Lung cancer, Ovarian cancer, AML, Lymphoma, and others, with CIN cases in AML being the lowest.
• Surprisingly, Japan accounts for the largest Chemotherapy Induced Neutropenia prevalence after the US in the 7MM. The driving factor for the highest cases in Japan is due to the high number of colorectal cancer cases. 
• Current treatments in the Chemotherapy Induced Neutropenia therapy market are limited to two approved biologics such as Neupogen (filgrastim) and Neulasta (pegfilgrastim) and their biosimilars.
• The Chemotherapy Induced Neutropenia market share of biologics is expected to decline owing to the entry of biosimilars as well as novel therapies. 
• Major key players leading the Chemotherapy Induced Neutropenia market size growth ahead include Spectrum Pharmaceuticals, Evive Biotech, Cellerant Therapeutics, BeyondSpring Pharmaceuticals, and others. 

 

Discover more about therapy, set to grab substantial CIN market share @ https://www.delveinsight.com/sample-request/chemotherapy-induced-neutropenia-cin-market

 

Chemotherapy Induced Neutropenia: Overview

Chemotherapy Induced Neutropenia (CIN) is the primary dose-limiting toxicity in patients undergoing cancer treatments with chemotherapy. It can lead to febrile neutropenia (FN), and it is associated with increased morbidity and early mortality, increased medical costs, and disruptions in potentially curative treatments. Some of the risk factors for CIN are older age, female gender, poor performance status, albumin level

 

Chemotherapy Induced Neutropenia Epidemiology Segmentation 

The Chemotherapy Induced Neutropenia market report puts forward the epidemiological analysis for the study period 2018-30 in the 7MM segmented into: 

• Total number of Patients on Chemotherapy
• Risk-specific Chemotherapy Patient Pool for CIN
• Total Incident Cases of CIN by Cancer-Type

 

Download report to understand which demographic factors are guiding the CIN epidemiology @ https://www.delveinsight.com/sample-request/chemotherapy-induced-neutropenia-cin-market

 

Chemotherapy Induced Neutropenia Pipeline Therapies 

• Rolontis (eflapegrastim injection): Spectrum Pharmaceuticals
• EC-18: Enzychem Lifesciences Corporation
• ALRN-6924: Aileron Therapeutics
• Romyelocel-L/CL T-008: Cellerant Therapeutics
• Myelo001: Myelo Therapeutics
• Plinabulin: BeyondSpring Pharmaceuticals
• F-627 (Ryzneuta): Evive Biotech

 

Check out for more @ https://www.delveinsight.com/sample-request/chemotherapy-induced-neutropenia-cin-market

 

Scope of the Chemotherapy Induced Neutropenia Market Report 

Coverage: 7MM (the US, EU5, and Japan)

Study Period: 2018-30

Key Companies: Spectrum Pharmaceuticals, Evive Biotech, Cellerant Therapeutics, BeyondSpring Pharmaceuticals, and others. 

Key Chemotherapy Induced Neutropenia Pipeline Therapies: Rolontis (eflapegrastim injection), EC-18, ALRN-6924, Romyelocel-L/CL T-008, Myelo001, Plinabulin, F-627 (Ryzneuta), and others. 

Chemotherapy Induced Neutropenia Market Segmentation: By Geography, By Chemotherapy Induced Neutropenia Therapies

Analysis: Comparative and conjoint analysis of Chemotherapy Induced Neutropenia emerging therapies

Tools used: SWOT analysis, Conjoint Analysis, Porter’s Five Forces, PESTLE analysis, BCG Matrix analysis methods.

Case Studies

KOL’s Views

Analyst’s Views

 

Table of Contents 

1	Key Insights
2	Chemotherapy Induced Neutropenia Market Report Introduction
3	Chemotherapy Induced Neutropenia Market Overview at a Glance
4	Executive Summary of Chemotherapy Induced Neutropenia
5	Disease Background and Overview
6	Algorithm for Diagnosis of Chemotherapy Induced Neutropenia
7	Patient Journey
8	Chemotherapy Induced Neutropenia (CIN) Epidemiology and Patient Population
9	Treatment Algorithm, Current Treatment, and Medical Practices
10	Chemotherapy Induced Neutropenia Epidemiology and Patient Population
11	Country Wise-Epidemiology of Chemotherapy Induced Neutropenia
10	Chemotherapy Induced Neutropenia Treatment
12	Unmet Needs
13	Key Endpoints of Chemotherapy Induced Neutropenia (CIN) Treatment
14	Chemotherapy Induced Neutropenia Emerging Therapies
15	Chemotherapy Induced Neutropenia: 7 Major Market Analysis
16	Chemotherapy Induced Neutropenia Market Unmet Needs
17	Case Reports
18	Chemotherapy Induced Neutropenia Market Drivers
19	Chemotherapy Induced Neutropenia Market Barriers
20	SWOT Analysis
21	KOL Reviews
21	Appendix
22	DelveInsight Capabilities
23	Disclaimer
24	About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market